Ketoconazole therapy in a dog with systemic cryptococcosis.

J Am Vet Med Assoc

Department of Small Animal Medicine, School of Veterinary Medicine, Tufts University, North Grafton, MA 01536.

Published: October 1989

A 2-year-old dog had bilateral chorioretinitis and a cough. Systemic cryptococcosis was diagnosed by evaluating a trans-tracheal aspirate and a cryptococcal latex-particle agglutination antigen titer. Clinical remission was achieved with ketoconazole administration, an imidazole antifungal agent. Serial antigen titers were used to monitor treatment, which was continued for 12 months. Ketoconazole therapy was well tolerated by the dog.

Download full-text PDF

Source

Publication Analysis

Top Keywords

ketoconazole therapy
8
systemic cryptococcosis
8
therapy dog
4
dog systemic
4
cryptococcosis 2-year-old
4
2-year-old dog
4
dog bilateral
4
bilateral chorioretinitis
4
chorioretinitis cough
4
cough systemic
4

Similar Publications

Advances in pharmacological treatment of Cushings disease.

Zhong Nan Da Xue Xue Bao Yi Xue Ban

July 2024

Department of Endocrinology &Metabolism, West China Hospital, Sichuan University, Chengdu 610041.

Cushing's disease is a rare endocrine disorder characterized by hypercortisolism. Chronic elevated cortisol levels can lead to dysfunction or complications in multiple organs of systems, including cardiovascular, glucose, and bone metabolism, severely impacting patients' quality of life and posing life-threatening risks. Surgery is the first-line treatment for Cushing's disease.

View Article and Find Full Text PDF

The current study aims to establish a novel ultra-deformable vesicular system to enhance the drug penetration across the skin by preparing the ketoconazole-loaded menthosomes. It was achieved through regular thin-film evaporation & hydration techniques. To examine the effect of formulation parameters on menthosome characteristics, a 2 full factorial design was used using Design-Expert® software.

View Article and Find Full Text PDF

Pharmacokinetic Boosting of Calcineurin Inhibitors in Transplantation: Pros, Cons, and Perspectives.

Ther Drug Monit

February 2025

Service de Pharmacologie, Toxicologie et Pharmacovigilance, CHU Limoges, Limoges, France.

The concept of pharmacokinetic (PK) boosting of calcineurin inhibitors (CNI) emerged after the FDA approval of cyclosporine-A. Several studies followed, and the proof of concept was well established by the late 1990s. This also continued for the next blockbuster immunosuppressant, tacrolimus.

View Article and Find Full Text PDF

Breast cancer stem cells (CSCs) are resistant to most cancer therapeutics and contribute to tumor recurrence and metastasis. Two breast CSC-promoting transcription factors, truncated glioma-associated oncogene homolog 1 (tGLI1) and signal transducer and activator of transcription 3 (STAT3), have been reported to be frequently co-expressed in HER2-enriched breast cancer and triple-negative breast cancer (TNBC), undergo protein-protein interactions for gene regulation and activation, and functionally cooperate to promote breast CSCs. STAT3 can be activated by activated interleukin-6 receptor/glycoprotein-130 (IL-6R/GP130).

View Article and Find Full Text PDF

Poloxamer 407 is a versatile excipient that enhances drug solubilization and prolongs drug release. Poloxamers are non-ionic tri-block copolymers composed of a central hydrophobic chain of polyoxypropylene flanked by two hydrophilic chains of polyoxyethylene. Various researchers have utilized Poloxamer 407 in topical and transdermal drug delivery systems, and it has also been reported to enhance skin permeability.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!